Researchers compared the perturbations of proteins in response to two treatments to human African trypanosomiasis, or sleeping sickness. The workflow identified the differences between NEU-4438 (“a lead for the development of drugs against Trypanosoma brucei,” the parasite responsible for sleeping sickness) and acoziborole, a more common treatment.

See the full list of authors and read their research paper at iScience: “Hypothesis-generating proteome perturbation to identify NEU-4438 and acoziborole modes of action in the African Trypanosome.”